首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1378699

阿拉吉尔症候群治疗药物市场：按药物、配销通路和地区

Alagille Syndrome Treatment Market, By Drug, By Distribution Channel, By Geography

出版日期: 2023年10月18日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2023 年，全球 Alagille症候群治疗市场将达到 8,890 万美元，预计在预测期内（2023-2030 年）年复合成长率为 6.6%。

报告范围		报告详情
基准年	2022年	2023年市场规模	8890万美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	6.60%	2030年市场规模预测	1.387 亿美元

图 1. Alagille症候群治疗药物的全球市场占有率（%），按药物划分，2023 年

阿拉吉尔症候群是一种遗传性疾病，会影响身体的不同部位，包括肝臟、心臟、眼睛、脸部、骨骼、血管和肾臟。阿拉吉尔症候群患者肝臟中的小胆管数量少于正常数量。胆管将来自肝臟的胆汁储存在胆囊中，并将其运送到小肠的第一部分（也称为十二指肠）以进行消化。当胆管较少时，从肝臟流出的胆汁就会减少。这种情况称为胆汁淤积。如果胆汁在肝臟中积聚，就会导致肝损伤。因此，在预测期内，用于治疗Alagille症候群的新药的引入预计将推动全球Alagille症候群治疗药物市场的成长。

市场动态

製药业的主要参与者正致力于开发具有不同方法和平台的新药来治疗 Alagille症候群。因此，将此类先进产品引入市场预计将在预测期内推动全球 Alagille症候群治疗药物市场的成长。例如，2023年6月13日，全球生物製药公司易普森製药公司宣布，美国食品药物管理局（FDA）已批准用于治疗12个月及以上阿拉吉尔症候群（ALGS）患者的胆汁淤积性搔痒症。Balllvay（odevixibat）作为药物的核准。

本研究的主要特点

本报告对全球Alagille症候群治疗药物市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030）的市场规模和復合年度（年复合成长率）。它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球阿拉吉尔症候群治疗药物市场的主要参与者进行了分析。
本研究涵盖的主要企业包括 Teva Pharmaceutical Industries Ltd.、AbbVie, Inc.、Glenmark Pharmaceuticals Limited、Par Pharmaceuticals, Inc.、Mylan Pharmaceuticals, Inc.、Sanofi SA、Mylan NV、Novartis International AG、Akorn, Inc.、Albireo Pharma, Inc.、Mirum Pharmaceuticals、Ipsen Pharma、CANbridge Pharmaceuticals, Inc. 等。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场经营团队和行销策略做出明智的资讯。
全球阿拉吉尔症候群治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球阿拉吉尔症候群治疗药物市场的各种策略矩阵来促进他们的决策。

公司简介
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi SA
- Mylan NV
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Ipsen Pharma
- CANbridge Pharmaceuticals, Inc.

第9章章节

参考
调查方法

简介目录

Product Code: CMI4398

The global alagille syndrome treatment market is estimated to be valued at US$ 88.9 Million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 88.9 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	6.60%	2030 Value Projection:	US$ 138.7 Mn

Figure 1. Global Alagille Syndrome Treatment Market Share (%), By Drug, 2023

Alagille Syndrome Treatment Market - IMG1

Alagille syndrome is a genetic disorder that may affect many different parts of the body including the liver, heart, eyes, face, skeleton, blood vessels, and kidneys. A person with Alagille syndrome has fewer than the normal number of small bile ducts inside the liver. Bile ducts carry bile from the liver to the gallbladder for storage and then to the first part of the small intestine, also called the duodenum, for use in digestion. With fewer small bile ducts, less bile flows out of the liver. This condition is called cholestasis. As bile builds up in the liver, it may cause liver damage. Thus, the introduction of new drugs for the treatment of alagille syndrome in the market is expected to drive the growth of the global alagille syndrome treatment market over the forecast period.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of new drugs with different approaches and platforms for the treatment of Alagille syndrome. Thus, the introduction of such advanced products in the market is expected to drive the growth of the global alagille syndrome treatment market over the forecast period. For instance, on June 13, 2023, Ipsen Pharma, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille Syndrome (ALGS).

Key features of the study:

This report provides an in-depth analysis of the global alagille syndrome treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global alagille syndrome treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Ipsen Pharma, and CANbridge Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global alagille syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alagille syndrome treatment market

Alagille Syndrome Treatment Market Detailed Segmentation:

By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi S.A.
- Mylan N.V.
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Ipsen Pharma
- CANbridge Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Diagnosis & Treatment Overview
- Key Developments
- PEST Analysis

4. Global Alagille Syndrome Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Alagille Syndrome Treatment Market, By Drug, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Ursodeoxycholic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

6. Global Alagille Syndrome Treatment Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

7. Global Alagille Syndrome Treatment Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018-2030, (US$ Mn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- AbbVie, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Glenmark Pharmaceuticals Limited
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Par Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Mylan Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Sanofi S.A.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Mylan N.V.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis International AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Akorn, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Albireo Pharma, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Mirum Pharmaceuticals
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Ipsen Pharma
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- CANbridge Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

阿拉吉尔症候群治疗药物市场：按药物、配销通路和地区

Alagille Syndrome Treatment Market, By Drug, By Distribution Channel, By Geography

市场动态

本研究的主要特点

目录

第1章研究目的与前提

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球 Alagille症候群治疗药物市场 – COVID-19 的影响分析

第5章全球 Alagille症候群治疗药物市场，依药物划分，2018-2030 年

第6章全球 Alagille症候群治疗药物市场，依配销通路，2018-2030 年

第7章2018-2030年全球Alagille症候群治疗药物市场（按地区）

第8章竞争形势